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Background:  Because the κ-opioid receptor (OR) agonist U50488H stimulates opioidergic regulation and inhibits 
L-type Ca
2+ channels, this study was aimed at assessing the roles of OR and L-type Ca
2+ channels on U50488H-
induced cardioprotection.
Methods:  Langendorff-perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. 
Isolated hearts were treated with U50488H with or without the κ-OR antagonist nor-binaltorphimine (nor-BNI) or 
the Ca
2+ channels activator BAY K 8644. Infarct size was measured with 2,3,5-triphenyltetrazolium chloride staining. 
Results:  U50488H treatment at reperfusion: (1) significantly reduced infarct size (11.3 ± 1.3%) compared to control 
hearts (27.7 ± 1.1%, P < 0.001), an effect that was completely blocked by nor-BNI (24.0 ± 0.9%, P < 0.001 vs. U50488H) 
but not by BAY K 8644 (7.1 ± 1.7%, P > 0.05 vs. U50488H); (2) significantly increased left ventricular developed 
pressure (65.3 ± 4.8%) after 2 h of reperfusion compared to control hearts (44.8 ± 3.6%, P < 0.05), an effect that was 
abrogated by nor-BNI (40.5 ± 4.5%, P > 0.05 vs. control) but not by BAY K 8644 (64.3 ± 5.6%, P < 0.01 vs. control); and (3) 
significantly decreased heart rate (P < 0.01 vs. control), an effect that was completely abrogated by both nor-BNI and 
BAY K 8644. 
Conclusions:  U50488H significantly limits myocardial infarction and stunning in isolated rat hearts after ischemia-
reperfusion induction. The infarct size limitation and contractility improvement observed with U50488H treatment 
during reperfusion are entirely mediated by OR stimulation and not by Ca
2+ channel modulation.  (Korean J 
Anesthesiol 2010; 58: 162-168)
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Introduction
    Recently, we reported that κ-opioid receptor (OR) activation 
by U50488H (trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-
pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride) 
during the early reperfusion phase reduced both myocardial 
infarction and stunning in isolated rat hearts [1]. Infarct size 
was reduced to more than 50% and cardiodynamic functional 
variables were well preserved compared to untreated control 
hearts. 
    A marked increase in intracellular Ca
2+ content ([Ca
2+]i) has 
also been reported in myocardial ischemia/reperfusion (I/R) 
injury [2,3]. Ca
2+ overload is a major cause of myocardial cell 
damage and cardiac dysfunction in ischemic hearts, and Ca
2+ 
overload evoked by reperfusion is associated with irreversible 
myocardial injury [4]. Cardiac L-type Ca
2+ channels are the 
main venue for Ca
2+ influx into cardiac cells, and the increase 
in[Ca
2+]i likely results in the depressed ability of I/R injured 
hearts to generate contractile force [5,6]. Therefore, inhibition 
of calcium channels has been proposed as an effective strategy 
against myocardial I/R injury [7,8]. Interestingly, U50488H is 
known to have an OR stimulation action as well as a non-opioid 
action that involves L-type Ca
2+ channel blockade, which is 
not antagonized by OR antagonism [9]. In this regard, one 
cannot rule out the role of Ca
2+ channels in U50488H-induced 
cardioprotection. 
    In the present study, we used a Ca
2+ channel activator in an 
isolated rat heart model to investigate if modulation of Ca
2+ 
channels plays a role in terms of both infarct size limitation and 
functional recovery in U50488H-mediated cardioprotection. 
Materials and Methods
Langendorff isolated heart perfusion preparation
    The experimental procedures and protocols used in this study 
were reviewed and approved by our Institutional Animal Care 
and Use Committee. Male Sprague-Dawley rats, weighing 280-
330 gm (obtained from Korea Taconic, Republic of Korea), 
were used for the experiments. They received 100 mg/kg of 
pentobarbital sodium (Entobar
Ⓡ, Hanlim Pharmacy, Yongin-
si, Korea) and 300 IU of heparin intraperitoneally. Hearts were 
isolated and perfused with modified Krebs-Henseleit (KH) 
solution containing 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 
24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose (in mM) as described 
in our previous reports [1,10]. 
Ischemia and reperfusion induction 
    Regional ischemia and reperfusion were induced as described 
in our previous report [10]. In brief, the proximal length of the 
left coronary artery (LCA) was localized followed by passage 
of a 6-0 polypropylene suture around the major trunk of the 
LCA or its prominent branches. The ends of the thread were 
passed through a small piece of PE 50 plastic tube to form a 
snare. Regional ischemia was induced by pulling the snare and 
confirmed by regional cyanosis, a substantial decrease in left 
ventricular developed pressure (LVDP), or a fall of coronary 
flow (CF). Reperfusion was induced by releasing the ends of the 
suture. 
Assessment of cardiac function
    In isolated hearts, a latex balloon was inserted into the left 
ventricle through the left atrial appendage. Balloon volume 
was adjusted with KH buffer to 5-10 mmHg of the left 
ventricular end-diastolic pressure (LVEDP) at the beginning 
of the experiment. CF was measured by timed collection of 
the perfusate dripping from the right heart into a graduated 
cylinder. 
    Hemodynamic data, including heart rate (HR), left ventricular 
systolic pressure (LVSP), and LVEDP, were continuously 
recorded with the MP150 system (BIOPAC Systems Inc., CA). 
LVDP and rate-pressure product (RPP) were calculated as 
follows LVDP = LVSP - LVEDP and RPP = LVDP × HR. The 
maximum and minimum of the first derivative of left ventricular 
pressure (+dP/dtmax and -dP/dtmin) were analyzed with the 
Acqknowledge software, version 3.9.0. 
Experimental protocol 
    All hearts were allowed to stabilize for at least 20 min after 
hanging on the hearts to Langendorff apparatus and were 
subjected to 30 min of regional ischemia and 2 h of reperfusion. 
Each group consisted of at least 7 hearts. Isolated rat hearts 
were assigned randomly to one of the following six groups: 
1) CON (n = 9); control, no intervention either before or after 
LCA occlusion, 
2) U50 (n = 8); 1 μM of the standard selective κ-OR agonist 
U50488H, 
3) U50+BNI (n = 7); 1 μM U50488H combined with 5 μM of the 
standard κ-OR antagonist nor-binaltorphimine (nor-BNI), 
4) U50+BAY (n = 8); 1 μM U50488H combined with 10 μM of 
the L-type Ca
2+ channel activator BAY K 8644 (1,4-dihydro-
2,6-dimethyl-5-nitro-4-(-2-(trifluoromethyl)-phenyl)-3-
pyrinecarboxylic acid methyl ester), 
5) BNI (n = 7); nor-BNI alone, and 
6) BAY (n = 7); BAY K 8644 alone.
    U50488H, nor-BNI, and BAY K 8644 were purchased from 
Tocris Bioscience (Ellisville, MO, USA). The compounds were 164 www.ekja.org
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padministered over a period of 5 min before reperfusion, then 
again for 30 min after reperfusion. U50488H and nor-BNI were 
dissolved in distilled water and BAY K 8644 was dissolved in 
dimethyl sulfoxide. The concentrations of all chemicals were 
based on previous studies using isolated working rat hearts 
[1,11,12].
Determination of area at risk and infarct size
    At the end of each experiment, the area at risk (AR) and area 
of necrosis (AN) were measured as described previously [10]. 
Briefly, the LCA perfusion circuit was reoccluded, and diluted 
fluorescent polymer microspheres (Duke Scientific Corp., Palo 
Alto, MA, USA) were infused to demarcate the AR. The hearts 
were cut into 2-mm thick transverse slices using a rat heart 
slice matrix (Zivic Instruments, Pittsburgh, PA, USA). The slices 
were incubated in 1% 2,3,5-triphenyltetrazolium chloride 
(TTC) (Sigma-Aldrich Chemical, St. Louis, MO, USA) in sodium 
phosphate buffer (pH = 7.4) at 37
oC for 20 min and subsequently 
immersed in 10% formalin to enhance the contrast. The 
myocardial AR was identified by illuminating the slices with UV 
light. The infarcted (unstained with TTC) and risk zone regions 
(no fluorescent area) were traced on a clear acetate transparent 
sheet and quantified with UTHSCSA Image Tool, version 3.0 
(Department of Dental Diagnostic Science at The University 
of Texas Health Science Center, San Antonio, Texas, USA). The 
areas were converted into volumes by multiplying them by slice 
thickness. The AN volume was expressed as a percentage of the 
AR volume. All measurements were performed in a blinded 
fashion. There were no significant group differences with 
respect to body weight, heart weight, and LV volume (Table 1).
Statistical analysis
    Data are presented as means ± SEM. Data analysis was per-
formed with a personal computer statistical software package 
(SPSS for Windows, Release 12.0 SPSS Inc, Chicago, IL, USA). 
Data were analyzed using one-way analysis of variance (ANOVA) 
with Bonferroni post-hoc testing. Differences were considered 
to be statistically significant when P values were < 0.05.
Results
    Forty-six rat hearts were used for this experiment. All 
hearts were perfused within 30 sec after excision. Ventricular 
fibrillation (VF) occurred in 15 of 46 hearts (3/9 in CON, 2/8 in 
U50, 3/7 in U50 + BNI, 3/8 in U50+BAY, 2/7 in BNI, and 2/7 in 
BAY) during early reperfusion. Hearts experiencing VF usually 
revert spontaneously to sinus rhythm. VF that lasted more 
than 30 sec was treated with finger flick cardioversion until a 
perfusing rhythm was obtained. Statistical analysis was not 
performed for the occurrence of VF because of the small sample 
size in each group.
Determination of infarct size 
    Risk volume averaged 0.296 cm
3 to 0.340 cm
3 with no 
statistically significant differences among groups (P > 0.05). 
The AR/LV ranged from 59.3% to 70.4% with no significant 
differences among all groups (P > 0.05), suggesting that the 
changes in infarct size observed between various groups in our 
experiments were not related to the degree of ischemic area. 
    As shown in Fig. 1, the area of infarct in the control hearts was 
27.7 ± 1.1% of the AR, which is in agreement with our recently 
reported infarct measurement study [1,10]. U50488H treatment 
targeting reperfusion significantly reduced infarct size (11.3 ± 
1.3%) compared to untreated control hearts (P < 0.001). The 
U50488H-induced infarct limitation effect was completely 
attenuated by the selective κ-OR antagonist nor-BNI (24.0 
± 0.9%, P < 0.001 vs. U50) but not by the L-type Ca
2+ channel 
activator BAY K 8644 (7.1 ± 1.7%, P < 0.001 vs. CON). In the rats 
that received only nor-BNI or BAY K 8644, neither nor-BNI (23.7 
± 2.5%) nor BAY K 8644 (27.9 ± 1.4%) alone altered infarct size (P 
> 0.05 vs. CON).
Table 1. Morphometric Data
Group Body weight (gm) Heart weight (gm) LV volume (cm
3) AR volume (cm
3) AR/LV (%)
CON 308.1 ± 4.9 1.42 ± 0.24 0.523 ± 0.020 0.311 ± 0.011 59.8 ± 2.4
U50 308.6 ± 9.4 1.42 ± 0.03 0.499 ± 0.019  0.304 ± 0.019 61.1 ± 4.5
U50 + BNI 300.7 ± 4.9 1.42 ± 0.02 0.493 ± 0.007 0.310 ± 0.010 63.0 ± 2.4
U50 + BAY 306.6 ± 4.7 1.38 ± 0.03 0.550 ± 0.030 0.340 ± 0.020 63.7 ± 5.8
BNI 300.0 ± 4.9 1.42 ± 0.02 0.489 ± 0.020 0.339 ± 0.009 70.4 ± 4.1
BAY 306.4 ± 6.0 1.43 ± 0.05  0.504 ± 0.009 0.296 ± 0.013 59.3 ± 3.0
Values are means ± SEM. U50: a U50488H, κ–opiopid receptor agonist, BNI: nor-binaltorphimine, a selectiveκ–opioid receptor antagonist, 
BAY: BAY K 8644, an L-type calcium channel activator, LV: left ventricle, AR: area at risk.165 www.ekja.org
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Cardiac functional recovery 
    There were no significant baseline differences in CF or in 
hemodynamic indices, namely HR, LVDP, RPP, +dP/dtmax, and 
-dP/dtmin among the groups (Table 2). CF abruptly decreased 
after ischemia and diminished continuously during reperfusion 
without significant differences among groups (data not shown). 
After 2 h of reperfusion, the LVDP, RPP, +dP/dtmax, and -dP/dtmin 
in control hearts were 44.8 ± 3.6%, 42.9 ± 3.8%, 47.8 ± 3.3%, and 
45.0 ± 1.9% of the baseline levels, respectively, and these results 
are in agreement with a previous report in isolated rat hearts [1]. 
HR was significantly decreased in U50488H-treated hearts (P < 0.01 
vs. CON, Fig. 2). Both BNI and BAY K 8644 completely abrogated 
the decrease in HR in U50488H-treated hearts (P < 0.05 vs. U50, 
Fig. 2). 
    As shown in Fig. 3, U50488H significantly increased LVDP 
after reperfusion (65.3 ± 4.8%, P < 0.05 vs. CON). The increase 
in LVDP by U50488H was abrogated by nor-BNI (40.5 ± 4.5%, 
P < 0.01 vs. U50) but not by BAY K 8644 (64.3 ± 5.6% P > 0.05 
vs. U50). There was no significant change in RPP between 
U50488H-treated hearts (49.1 ± 3.6%) and untreated control 
hearts. Administration of BAY K 8644 in U50488H-treated hearts 
(68.1 ± 6.4%) significantly increased RPP compared to both 
control and U50488H-treated hearts (P < 0.01). +dP/dtmax and 
-dP/dtmin exhibited a tendency to increase in U50488H-treated 
hearts but there were no significant differences compared 
to control hearts (P > 0.05, Fig. 4). When control hearts were 
compared to hearts first treated with U50488H then with either 
BNI or BAY K 8644, there were no significant differences in 
cardiodynamic variables. 
Group 
Coronary flow
(ml/min) 
Heart rate
(beats/min) 
LVDP
(mmHg) 
RPP
(mmHg·beats/min·10
3) 
+dP/dtmax 
(mmHg/s/10
3)
-dP/dtmin
(mmHg/s/10
3) 
CON 14.2 ± 0.5 283.6 ± 8.1 108.1 ± 7.6   30.5 ± 1.9 2.8 ± 0.1 -2.8 ± 0.2
U50  13.6 ± 0.9   273.8 ± 11.0 107.1 ± 7.8 29.5 ± 2.8 3.1 ± 0.4 -2.6 ± 0.0
U50 + BNI 13.3 ± 0.5 278.5 ± 3.5   111.5 ± 10.2 31.1 ± 2.8 3.0 ± 0.4 -2.5 ± 0.2
U50 + BAY 12.2 ± 0.6 281.4 ± 3.7 116.7 ± 7.7 32.8 ± 2.2 2.7 ± 0.3 -2.6 ± 0.3
BNI 12.6 ± 0.7 291.7 ± 7.4 117.0 ± 4.7 34.0 ± 1.4 2.7 ± 0.2 -2.5 ± 0.2
BAY 13.0 ± 0.2   281.3 ± 10.2   121.8 ± 11.2 34.0 ± 2.8 2.4 ± 0.1 -2.5 ± 0.2
Values are means ± SEM. U50: U50488H, a κ–opiopid receptor agonist, BNI: nor-binaltorphimine, a selective κ–opioid receptor antagonist, 
BAY: BAY K 8644, an L-type calcium channel activator, LVDP: left ventricular developed pressure, RPP: rate-pressure product, +dP/dtmax: veloc-
ity of contraction, -dP/dtmin: velocity of relaxation. There were no significant differences among groups. 
Table 2. Baseline Coronary Flow and Cardiodynamic Data after Stabilization 
Fig. 1. Area of necrosis (AN) as percentage of area at risk (AR) as 
evaluated by triphenyltetrazolium chloride staining following 30 min 
regional ischemia and 2 h reperfusion in an isolated rat heart model. 
U50488H treatment during the early reperfusion period greatly re-
duces infarct size. Infarct size limitation by U50488H treatment is 
completely abolished by the selective κ-OR antagonist nor- binal-
torphimine but not by the L-type Ca
2+ channel activator BAY K 8644. 
CON: control, U50: U50488H, BNI: nor-binaltorphimine, BAY: BAY K 
8644. Each circle represents 1 heart. Horizontal bars depict mean of 
the group. Values are means ± SEM. *P < 0.05 vs. CON.
Fig. 2. Percentage changes in heart rate (HR) after 30 min regional 
ischemia and 2 h reperfusion. HR is significantly decreased in 
U50488H-treated hearts. Both nor-binaltorphimine and BAY K 8644 
completely blocks the decrease in HR in U50488H-treated hearts. 
CON: control, U50: U50488H, BNI: nor-binaltorphimine, BAY: BAY K 
8644. Values are means ± SEM. *P < 0.05 vs. CON, 
†P < 0.05 vs. U50. 166 www.ekja.org
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Discussion
      Because U50488H inhibits L-type Ca
2+ currents in guinea pig 
ventricular myocytes without OR binding involvement [9] and 
U50488H increases [Ca
2+]i in isolated rat ventricular myocytes, 
an effect that is antagonized by κ-OR antagonists [13], there is a 
controversy about the role of Ca
2+ channels in U50488H-induced 
cardioprotection. 
    In the present study, treatment with the κ-OR agonist 
U50488H at reperfusion significantly decreased myocardial 
infarction and stunning in isolated rat hearts; these results 
are consistent with our recent previous report [1]. U50488H-
mediated infarct size limitation was totally abrogated by 
the κ-OR antagonist nor-BNI, but not by the L-type Ca
2+ 
channel activator BAY K 8644, implying that the infarct size 
limitation effect by U50488H at reperfusion is solely caused by 
OR activation and not by Ca
2+ channel inhibition. In addition, 
U50488H significantly improved myocardial contractility, as 
reflected by LVDP, after reperfusion. LVDP recovered to 65.3% of 
the baseline level (44.8% in U50488H-untreated control hearts). 
The increase in LVDP was completely blocked by nor-BNI, 
suggesting that the recovery of LVDP associated with U50488H 
treatment was induced by κ-OR activation. However, BAY K 
8644 could not attenuate U50488H-mediated recovery of LVDP, 
which argues against L-type Ca
2+ channel involvement. Taken 
together, our data strongly suggest that cardioprotection by 
U50488H is mediated by opiodergic regulation but not by Ca
2+ 
channel modulation. 
Fig. 3. Percentage changes in left ventricular developed pressure (LVDP) and rate-pressure product (RPP) after 2 h of reperfusion compared 
to baseline levels in isolated rat hearts. U50488H significantly increases LVDP after reperfusion. The increase in LVDP by U50488H is blocked 
by nor-binaltorphimine but not by BAY K 8644. There is no significant change in RPP between U50488H-treated hearts and untreated control 
hearts. CON: control, U50: U50488H, BNI: nor- binaltorphimine, BAY: BAY K 8644. Values are means ± SEM. *P < 0.05 vs. CON, 
†P < 0.05 vs. 
U50 + BNI.
Fig. 4. Percentage changes in velocity of contraction (+dP/dtmax) and velocity of relaxation (-dP/dtmin) after 2 h of reperfusion compared to 
baseline in isolated rat hearts. There are no statistical significances among the groups. CON: control, U50: U50488H, BNI: nor- binaltorphimine, 
BAY: BAY K 8644. Values are means ± SEM. 167 www.ekja.org
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    U50488H treatment targeting reperfusion significantly 
decreased HR. Notably, this effect was completely blocked 
by both nor-BNI and BAY K 8644. It has been demonstrated 
that BAY K 8644 treatment itself may increase or not change 
HR [14,15]. Though our concentration (10 μM) of BAY K 
8644 by itself did not alter HR compared to control hearts, 
this concentration of BAY K 8644 completely attenuated the 
decrease in HR by U50488H. This result strongly suggests that 
the decrease in HR by U50488H is modulated by both OR 
activation and Ca
2+ channel inhibition. The RPP (product of 
LVDP and HR) in U50488H-treated hearts was not statistically 
different from that in U50488H-untreated control hearts, 
although U50488H significantly increased LVDP after 
reperfusion. This result might be secondary to the combination 
of the decrease in HR and the increase in LVDP induced by 
U50488H. 
    It is well accepted that Ca
2+ ions are major regulators of 
cardiac function. Hypoxia and ischemia produce depression 
of myocardial contractile function and alterations in Ca
2+ 
homeostasis and reoxygenation or reperfusion can also lead to 
paradoxical augmentation of injury [16]. It appears as if [Ca
2+]
i overload is a recognized common pathway that underlies 
myocardial I/R injury [17]. The L-type Ca
2+ channel, a type 
of voltage-dependent Ca
2+ channel, is considered the most 
significant Ca
2+ entry portal into cardiac myocytes. The small 
amount of Ca
2+ entering the cytosol through this channel 
triggers the release of additional Ca
2+ from the sarcoplasmic 
reticulum. Accordingly, it has been proposed that lowering 
sarcolemmal Ca
2+ content may be a mechanism underlying 
cardioprotective and anti-arrhythmic features [18,19] and 
that inhibition of Ca
2+ channels may protect I/R injured 
myocardium by retardation of an early rise in [Ca
2+]i [20]. 
Indeed, there are several lines of evidence that Ca
2+ channel 
antagonists effectively treat myocardial I/R injury [8,21,22]. 
However, in our study, U50488H reduced myocardial infarction 
and stunning via OR stimulation but not by Ca
2+ channel 
modulation, even though there is evidence that U50488H also 
inhibits L-type Ca
2+ channels in ventricular myocytes [9]. 
    In conclusion, the κ-OR agonist U50488H significantly limits 
myocardial infarction and stunning in I/R-injured isolated rat 
hearts. The infarct size limitation by U50488H is mediated by OR 
stimulation but not by Ca
2+ channel modulation. In addition, 
the improved contractility by U50488H is also induced by OR 
activation and not by Ca
2+ channel inhibition. In contrast, the 
decrease in HR by U5048H is mediated by both OR activation 
and Ca
2+ channel inhibition.
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